20/20 Biolabs, Inc. (AIDX) received a notification from Nasdaq on September 3, 2026, indicating it is not in compliance with the minimum stockholders' equity requirement. This is in addition to a previously disclosed failure to meet the minimum bid price rule, increasing the risk of delisting.
Key Details
- Equity Shortfall: The company's reported stockholders' equity was $1,620,700 as of June 30, 2026, which is below the required minimum of $2,500,000 under Nasdaq Listing Rule 5550(b)(1).
- Compliance Plan: AIDX has 45 calendar days to submit a plan to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 days to meet the requirement.
- Existing Bid Price Issue: This new deficiency complicates the company's existing non-compliance with the $1.00 minimum bid price rule. Failure to resolve the equity issue by January 13, 2027, will make the company ineligible for a second compliance period for the bid price rule.